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ABSTRACT
Introduction Micronutrient deficiencies, commonly 
referred to as ‘hidden hunger’, affect more than two 
billion people worldwide, with zinc and iron- deficiency 
frequently reported. The aim of this study is to examine the 
impact of consuming zinc biofortified flour (Zincol-2016) 
on biochemical and functional measures of status in 
adolescent girls and children living in a low- resource 
setting in Pakistan.
Methods and analysis We are conducting a pragmatic, 
cluster- randomised, double- blind, controlled trial. A 
total of 482 households have been recruited from two 
catchment areas approximately 30–40 km distance from 
Peshawar. Household inclusion criteria are the presence 
of both an adolescent girl, aged 10–16 years, and a 
child aged 1–5 years. The study duration is 12 months, 
divided into two 6- month phases. During phase 1, all 
households will be provided with locally procured flour 
from standard varieties of wheat. During phase 2, clusters 
will be paired, and randomised to either the control or 
intervention arm of the study. The intervention arm will 
be provided with zinc biofortified wheat flour, with a 
target zinc concentration of 40 mg/kg. The control arm 
will be provided with locally procured wheat flour from 
standard varieties with an expected zinc concentration 
of 20 mg/kg. The primary outcome measure is plasma 
zinc concentration. Secondary outcomes include 
anthropometric measurements, biomarkers of iron and 
zinc status, and the presence and duration of respiratory 
tract infections and diarrhoea.
Ethics and dissemination Ethical approval was granted 
from the University of Central Lancashire STEMH Ethics 
Committee (reference number: STEMH 1014) and Khyber 
Medical University Ethics Committee (DIR/KMU- EB/
BZ/000683). The final study methods will be published in 
peer- reviewed journals, alongside the study outcomes. 
In addition, findings will be disseminated to the scientific 
community via conference presentations and abstracts 
and communicated to the study participants through the 
village elders at an appropriate community forum.
Trial registration number ISRCTN17107812; Pre- results.
INTRODUCTION
Micronutrient deficiency, commonly referred 
to as ‘hidden hunger’, affects more than two 
billion people worldwide, with the highest 
burden occurring in low- income and middle- 
income countries (LMICs).1 Zinc and iron 
are two of most frequently reported micro-
nutrient deficiencies, due in part to their low 
bioavailability from plant food sources which 
make up most of the calorie intake in low- 
resource communities. In Pakistan, the recent 
National Nutrition Survey (NNS) reported 
that 22.1% of women of reproductive age 
(WRA) and 18.6% of children under 5 years 
of age are zinc deficient.2 Although this is an 
improvement since the last NNS survey in 
Strengths and limitations of this study
 ► The study will build on and scale up our previous 
Biofortified Zinc Flour to Eliminate Deficiency trial, 
with a focus on adolescent girls and children, and 
will include both biochemical and functional bio-
markers of zinc status.
 ► Iron status will also be monitored as a secondary 
outcome measure because our previous study re-
vealed that the Zincol-2016 biofortified wheat has 
greater iron and zinc concentrations compared with 
control grain.
 ► The Zincol-2016 used in the effectiveness study will 
be grown by local farmers, therefore, giving a real-
istic picture of what is possible if the distribution of 
the grain was scaled up.
 ► A limitation is that, since designing the study, a flour 
fortification programme has been initiated in this re-
gion and some of the locally purchased flour may be 
fortified with iron, zinc and folate, although this will 
not impact on our primary outcome measure.
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2011, where the values were 41.9% and 36.5%, respec-
tively, the national survey headline does not reflect the 
situation in some of the most marginalised communities. 
Results from our own research focusing on communities 
living in the brick kiln areas around Peshawar revealed 
that the prevalence of zinc deficiency among WRA is 
30%, based on the prevalence of plasma zinc concen-
tration below 660 µg/L.3 The health consequences of 
zinc deficiency include greater risk of stunted growth 
and impaired neurodevelopment in children, increased 
susceptibility to infections in children and adults, and 
complications during the pregnancy and childbirth.3 
Diarrhoea is a major cause of morbidity and mortality in 
children under 5 years in LMICs, and both upper respi-
ratory tract infections and diarrhoea respond positively to 
zinc supplementation.4
According to the NNS, iron- deficiency anaemia (IDA) 
affects 18.2% of WRA and 28.6% of children <5 years. This 
is a modest improvement since 2011 (19.9% and 33.4%, 
respectively).2 IDA affects maternal and child mortality, 
physical and cognitive development in children and work 
productivity in adults.5
The Food Fortification Programme (FFP) in Pakistan 
was launched in 2016 and seeks to provide support to 
industry to adequately fortify wheat flour with iron and 
folate, and edible oil/ghee with vitamin A. The FFP is 
also supporting government capacity and infrastructure 
for laboratory testing, so that fortification is conducted 
to meet quality standards. This approach is undoubtedly 
an important part of the solution to hidden hunger in 
Pakistan; however, fortification of wheat flour will only 
reach those who purchase flour from mills participating 
in this programme. Over 60% of Pakistan’s wheat harvest 
is retained by farmers for self- consumption or used as 
in- kind payments to labourers.6 Most of this wheat is 
milled locally and not in the large industrial mills where 
flour fortification occurs.
An increasing body of evidence suggests that biofortifi-
cation, a process by which the nutritional quality of food 
crops is enhanced through plant breeding and/or agro-
nomic practices, may be a cost- effective and sustainable 
approach to reducing micronutrient deficiency, and may 
complement other strategies including fortification at 
processing stage and dietary diversification. A key chal-
lenge here is to assess the impact of biofortification in the 
context of spatially variable soils, with different concen-
trations of plant- available zinc; differences in basic soil 
properties that affect zinc uptake and in crops that are 
subject to differing management strategies, given the 
variations in resource endowment of farmers and in their 
environment.
Biofortified Zinc Flour to Eliminate Deficiency 
(BIZIFED2) follows on from our recently completed 
project, BiZiFED: (May 2017–April 2019). BiZiFED was 
a Foundation Award, funded by the Biotechnology and 
Biological Sciences Research Council (BBSRC) under the 
Global Challenges Research Fund (BB/P02338X/1).7 8 
BIZIFED2 will build on our previous study by exploring 
the impact of consuming flour milled from biofortified 
wheat grain (Zincol-2016) on biochemical and func-
tional indices of zinc and iron status in adolescent girls 
and children living in a low- resource setting in North 
West Pakistan. Adolescence is a critical time in the life 
course for physical and psychosocial development and 
attention to adolescent girls’ nutrition is an important 
preventive strategy that has the potential to improve 
adolescent girls’ health, including cognitive function, 
maternal and neonatal outcomes and the future health 
of their offspring. Investing in the health and develop-
ment of adolescents is, therefore, essential for achieving 
the Sustainable Development Goals, promoting public 
health and ensuring economic development.
The objective of this study is to examine the impact of 
consuming zinc biofortified flour on biochemical and 
functional measures of zinc status in adolescent girls and 
children. Secondary objectives are to quantify the contri-
bution to total dietary zinc and iron from biofortified 
flour, the impact of consuming the biofortified flour on 
iron status and to examine the bioavailability of zinc and 
iron from the flour.
METHODS AND ANALYSIS
Study setting and recruitment
The study is taking place in Khyber Pakhtunkhwa (KP) 
Province. There are two neighbouring catchment areas, 
A (5 km2) and B (4.5 km2), located 30–40 km south east 
of Peshawar. Area A was the location of our previous 
study, and a good working relationship with this commu-
nity has already been established, along with a detailed 
knowledge of the nutritional status of the WRA. Area B 
has not been involved in previous research conducted by 
this team, however, a good relationship with our imple-
mentation partner, Abaseen Foundation Pakistan (AFPK) 
was already in place as a result of an established AFPK 
education project. Cocreation of the research questions 
and dissemination of findings is embedded within the 
long- term relationship between the project partners and 
achieved through ongoing engagement with the commu-
nity and Jirga (respected male elders) and in accordance 
with the Global Code of Conduct.9 In order to assess 
the willingness and suitability of Area B as a catchment 
area for this study, a consultation was undertaken with 
the community Jirga where the purpose of the study 
was explained and discussed. With the Jirga’s permis-
sion, a pilot study of 50 WRA living in households within 
this area was undertaken to assess their dietary patterns 
(macro and micronutrient intakes), zinc status and the 
mineral content of the ground water used for drinking 
and cooking. The pilot study confirmed that there were 
no statistically significant differences [between area A 
and B] in either the dietary zinc or iron intake (p=0.73, 
p=0.89, respectively), or plasma zinc concentration 
(p=0.18). Groundwater mineral concentrations were 
compared with data collected previously from community 
A and found to be within a comparable range. In both 
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areas, the diet is low in animal- source foods and wheat 
is the staple. The wheat flour is purchased locally from 
the market and used for making paratha, chapatti and 
roti within the household, which are consumed with 
every meal. Fish is not part of the local diet, and meat is 
consumed rarely. Approximately 30% of the WRA have 
a plasma zinc concentration that falls below the cut- off 
value of 660 µg/L for adequacy.3
The households are located in clusters of variable size, 
defined by their geographical proximity. Areas A and 
B comprised 23 and 21 clusters (hamlets), respectively 
(figure 1). Area A has a health centre, managed and 
supported by AFPK, that serves as the field team hub and 
the location for blood sampling and healthcare support 
during the study. Area B did not have a suitable existing 
health centre, therefore, some rooms at the AFPK oper-
ated school in this community have been coopted for this 
purpose and alternative classrooms provided elsewhere in 
the building.
The study field team have undertaken a comprehensive 
mapping and baseline survey of the catchment area in 
June–September 2019. The total population is approxi-
mately 20 000 individuals in approximately 2000 house-
holds. Eligibility to participate in the trial was defined as 
households with at least one unmarried adolescent girl 
(10–16 years) and one child (1–5 years). Household eligi-
bility was recorded, along with household size (number 
of individuals cooking and eating together), during the 
baseline survey and used in the cluster selection and 
randomisation process described below.
Patient and public involvement
Cocreation of the research questions and dissemination 
of findings is embedded within the long- term relation-
ship between the project partners and achieved through 
ongoing engagement and dialogue with the community 
and Jirga. Families express concern in community meet-
ings about the health and well- being of their children 
and understand the relationship between diet and health. 
Figure 1 CONSORT flow diagram, schematic overview of the cluster selection procedure. CONSORT, Consolidated Standards 
of Reporting Trials.
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The community members were not directly involved in 
the design of this study, however, they are involved in 
conducting the study. We have employed women from 
the community to undertake the fortnightly health 
survey data collection and to report any concerns about 
the study or other general issues to the study manager. 
We have employed men from the community to monitor 
the flour stores and facilitate distribution to participating 
families. The findings of the study will be communicated 
to the study participants through the Jirga at an appro-
priate community forum.
Cluster selection and randomisation procedure
Clusters were ranked as a function of mean eligible house-
hold size (from smallest to largest). Starting from clusters 
with the smallest average family size, and working down 
the ranked order, clusters were included until the target 
sample size was reached. This resulted in an initial selec-
tion of 28 clusters (14 from each area) composed of 483 
eligible households. The cluster selection was not based 
on their location; the equal distribution between the two 
areas was serendipitous, but beneficial in terms of field 
team logistics enabling an equal spread of field activity 
between the two areas.
A follow- up survey of all households within the included 
clusters was undertaken in September 2019 to assess 
willingness to participate in the study, using a complete 
enumeration method. The head of each household was 
approached, and the purpose of the study explained. If 
the head of the household was willing, the adolescent girl 
and the mother of the child were approached and the 
purpose of the study explained, along with the partici-
pant information which was provided in written form 
in the local language (Pushto) and explained verbally. 
Consent to participate was indicated by signing with 
initials or an ‘X’ on the consent form. In households 
where there were two eligible adolescents and children, 
both pairs were invited to participate. A sample consent 
form can be found in online supplemental file 1. A total 
of 19 eligible households declined to participate, there-
fore, two additional clusters were selected based on the 
number of eligible households in the cluster and surveyed 
for willingness to participate. This resulted in a total of 
482 participating households from 30 clusters; 15 from 
area A and 15 from area B.
During the first data collection phase of the study in 
November–December 2019 (time point 1) several house-
holds withdrew from the study. Two further clusters from 
each area were selected based on the mean household 
size. The final number participants were 509 adolescent/
child pairs from 482 households located in 34 clusters 
(figure 1).
To help ensure comparability of the intervention and 
control clusters with respect to baseline criteria, the clus-
ters will be matched into pairs according to the average 
household size of the cluster and the age of the partic-
ipating adolescent girl. Many investigators conducting 
community intervention- based trials have shown that 
matching is a useful mechanism for creating comparable 
groups at baseline10 and mediated good face validity with 
regard to a balance between trial allocation arms.11 Within 
each pair of clusters, one will be allocated to receive the 
intervention flour and the other to receive control flour, 
the allocation being done at random with each cluster 
having an equal prior probability of being allocated to 
the intervention treatment.12 The random allocation 
of clusters to either intervention or control will be via a 
computer- generated software application (Random Allo-
cation Software). Only the study director (MZA), who is 
not directly involved in the data collection or analysis, will 
have access to the recorded allocation for each cluster.
The participants and all the research team members, 
including the principal investigator (PI) and co- PIs 
(except MZA), field team, laboratory scientists, database 
manager and data analysts will remain blind to the allo-
cation of the clusters to the intervention or control arm 
of the study. A data monitoring committee (DMC) will 
be assigned (from staff within the Clinical Trials Unit at 
Khyber Medical University (KMU), who are not involved 
in the study) and will have access to unblinded data from 
the trial. The DMC will review the interim data analyses 
including adverse events at three periods during the study 
and advise the steering committee whether the study 
needs to be changed, un- blinded or terminated based on 
these analyses. The three review periods have been iden-
tified as follows:
Review period 1: May 2020 (data collected during the 
baseline and midpoint of phase 1).
Review period 2: August 2020 (data collected at the end 
of phase 1 and preliminary data for phase 2).
Review period 3: October 2020 (data collected at the 
midpoint of phase 2).
Local production of Zincol-2016 grain for the intervention 
study
Forty farmers, with a combined growing area of 100 hect-
ares in close proximity to Peshawar (25 km from the study 
communities), have given consent to grow Zincol-2016 
wheat grain for onward use in the effectiveness study with 
support from Fauji Fertilizer Company (FFC), a collab-
orating organisation within the BIZIFED2 consortium. 
Soil samples from each of the fields have been analysed 
for organic and mineral content by FFC soil testing lab 
to secure site- specific fertiliser advice for each of the 40 
farms according to standard agronomic practice. Farmers 
have been provided with the Zincol-2016 grain, soil and 
foliar fertilisers as per this advice. The wheat produced by 
the farmers will be purchased at a favourable rate. The 
grain was sown between mid- October and mid- November 
2019 and will be closely monitored by a Regional Agron-
omist of FFC. Zinc foliar spray (0.1% elemental zinc; 303 
g of ZnSO4.H2O in 100 L of water used over 0.4 ha of 
crop) will be applied at booting stage, heading stage and 
a week after head emergence. Harvest will take place in 
April/May 2020, and the resulting grain will be milled 
and provided to families during phase 2 of the study 
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(figure 2). Control grain for phase 2 will be purchased 
from commercial farms in Punjab province, and milled 
locally for distribution to clusters in the control arm of 
the study. Prior to the start of phase 2, the zinc content 
of the control and intervention grain will be determined. 
The target grain zinc concentrations for the control and 
intervention grains are 20 and 40 mg/kg, respectively. 
In the unlikely event that there is no difference in grain 
Zn concentrations the trial will be terminated. The iron 
content of the Zincol-2016 grain and the control grain 
will be monitored for comparison and interpretation of 
the iron status biomarkers in the participants.
Study design
We are conducting a cluster- randomised, double- blind, 
controlled trial. The study will be undertaken in full 
compliance with the Consolidated Standards of Reporting 
Trials (CONSORT) guidelines for cluster randomised 
analyses.13 A cluster randomised trial is necessary due 
to the community- based nature of the intervention and 
to reduce the likelihood of contamination, since neigh-
bouring households regularly share flour or consume 
meals together.14 To estimate the sample size to detect a 
48 µg/L change in plasma zinc concentration, based on 
data from the previous trial, the following information 
was used: (1) a pragmatic and conservative estimate of the 
likely intraclass correlation coefficient (ICC) taking into 
account the recommendations of Hemming and Taljaard 
15 for a moderate ICC value (ICC=0.1); (2) similarly a prag-
matic estimate of the expected average cluster size based 
on discussions with the Pakistan field team leader (n=15); 
(3) to account for unequal cluster sizes an estimate of the 
coefficient of variation of cluster sizes (0.55 was calculated 
using the equation of Eldridge et al16) taking into account 
the expected mean cluster size as well as the expected 
range of cluster sizes, similarly based on discussions with 
the Pakistan field team; (4) a significance level at 5% and 
power of at least 90%; (5) an estimated likely attrition rate 
of 20%. The sample size that was yielded was N=500. The 
trial is composed of two 6- month phases, starting on the 
4 November 2019. The purpose of phase 1 is to establish 
baseline values for the outcome measures and the intra- 
individual variation over a 6- month period while the 
participating household are following their usual dietary 
patterns. During phase 1, all households in the partic-
ipating clusters will be provided with flour purchased 
locally, with three data collection points at the start, 
middle and end of phase 1. Phase 2 will start in month 7 
(May 2020) during which half of the clusters will receive 
the locally grown biofortified flour and half will receive 
control flour for a period of 6 months with data collection 
points at the middle and endpoint of phase 2 (figure 2). 
Sufficient flour for all the household members (calculated 
based on the household size, and the flour consumption 
rate reported during recruitment) will be distributed fort-
nightly throughout phase 1 and phase 2, and batches of 
flour will be sampled to monitor the iron, zinc and phytate 
content. Participants will collect the flour from a distribu-
tion point on presentation of a voucher. Sacks of control 
and biofortified flour will be identical and labelled using a 
unique alpha numeric code which does not disclose which 
type of flour is contained within to the participants but 
can be used to monitor adherence and fidelity of treat-
ment allocation. Compliance, including the purchase of 
any addition flour from the market, or any flour received 
from neighbours will be monitoring during the five data 
collection time points.
Figure 2 Schematic overview of the study design. FFC, Fauji Fertilizer Company; RTI, respiratory tract infection.
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Outcome measures
The aim of the randomised controlled trial (RCT) is 
to assess the impact of consuming biofortified flour on 
biochemical markers of zinc and iron status in adoles-
cent girls, and functional outcome measures in adoles-
cent girls and children. The outcome measures pertain 
to the participant not the cluster. The primary outcome 
measure is plasma zinc concentration, adjusted for inflam-
matory markers. The method for this has been described 
in detail previously.7 In brief, whole blood samples will be 
collected into trace element free tubes (BD Vacutainer, 
BD Diagnostics, Switzerland), centrifuged and the plasma 
removed within 40 min. Plasma will be stored on ice at the 
health centre until transfer and storage at −20°C at KMU 
within 24 hours. Zinc and other mineral concentrations in 
the plasma will be measured simultaneously using induc-
tively coupled plasma- mass spectrometry at the University 
of Nottingham, UK. Seronorm Trace Elements Serum 
level 1 and 2 (Nycomed Pharma AS, Billingstad, Norway) 
will be used as the certified reference materials to verify 
accuracy of the above multielement analyses. Inflamma-
tory markers, alpha 1- acid glycoprotein (AGP) and C 
reactive protein (CRP) will be measured using commer-
cial kits and Abbott Architect ci8200 automated analyser 
(Abbott, Abbott Park, Illinois, USA) at Rehman Medical 
Institute, Peshawar, Pakistan Multigen CRP Vario (Abbott 
Laboratories) immunoassay kit will used for the immuno-
turbidimetric determination of CRP in the plasma of the 
study participants. For immunoturbidimetric estimation 
of AGP, Quantia A-1- alpha 1- AGP assay kit (Abbott Labo-
ratories) will be used. Manufacturer’s instruction would 
be followed for performing the assays including the use 
of suggested calibrators and controls. Laboratory quality 
control performance will be tracked using Westgard rule 
criteria on the Levey- Jennings chart.
For adjusting plasma zinc concentration for inflamma-
tory markers, recent guidelines from International Zinc 
Nutrition Consultative Group will be followed.17 Briefly, 
correlation and decile analyses will be performed to 
understand the magnitude and direction of the associa-
tion between plasma zinc concentrations, CRP and AGP. 
Only, if the results of the correlation and decile analysis 
indicate a clear, negative association between plasma zinc 
concentrations and CRP and/or AGP, the Biomarkers 
Reflecting Inflammation and Nutritional Determinants 
of Anemia regression correction approach will be applied 
possibly including both CRP and AGP in the regression 
model.
Secondary outcome measures are as follows:
Additional biomarkers of zinc status
Measures of DNA damage using the Comet Assay, a novel 
biomarker of zinc status, will be taken on a random 
subsample of 100 adolescent participants, at three time 
points; baseline (end of phase 1), mid, and end of phase 
2. Whole blood will be transported from the field loca-
tion on ice to the laboratory (University of Peshawar) and 
processed within 2–3 hours according to the previously 
published protocol.18
Hair samples will also be collected from all adolescent 
participants at all five time points by combing through 
the hair and collecting those hairs from the comb that 
has cells from follicle attached to the proximal end of 
the hair as previously described.7 Zinc concentration of 
hair will be analysed exploiting a novel X- ray fluorescence 
technique.19
Biomarkers of iron status
Iron status will be assessed using serum transferrin 
receptor, serum ferritin concentrations. This will be 
undertaken at the Rehman Medical Institute, Peshawar, 
Pakistan. To measure soluble transferrin receptor, 
particle- enhanced immunoturbidimetric assay (Tina 
quant sTfR, Roche Diagnostics) on a fully mechanised 
analyzers Cobas 6000 (Roche Diagnostics) will be 
conducted. Ferritin will be quantified by a chemilumi-
nescent microparticle immunoassay technology based 
commercial kit (Architect ferritin 7K59, Abbott Labora-
tories) on by an automated analyzer (Abbott Architect 
ci8200, Abbott Laboratories, Abbott Park, Illinois, USA), 
These assays will be performed as per the manufacturer’s 
instruction including the run for recommended controls. 
Ferritin will be adjusted for inflammation (AGP and CRP) 
according to the latest guidelines by WHO.20
Haematology
Complete blood count, haematocrit, haemoglobin and 
mean corpuscular volume will be estimated using stan-
dard automated clinical haematology methods at the 
field site health centre.
Functional indicator of zinc status
Incidence and duration of diarrhoeal episodes (chil-
dren only) and respiratory tract infections (children 
and adolescent girls) will be recorded every 2 weeks 
throughout the study, through interview with the mother 
(for the child) and adolescent girl by the female commu-
nity worker assigned to that cluster.
Anthropometry
Anthropometric measures of children and adolescent 
girls will be made at all five data points, including height 
(or length in the children aged 1–2 years), weight, mid- 
upper arm circumference. In addition, waist and hip 
circumference measures will be made in adolescent girls, 
and head circumference will be measured in children at 
all five time points.
Diet analysis
Overall nutrient intake from the diet and the contribu-
tion to total dietary zinc and iron from biofortified flour 
will be quantified. Dietary nutrient intake will be assessed 
by multiple pass 24 hours recall. Within each household, 
the adolescent girl and the mother of the young child will 
be interviewed by a study nutritionist and portion sizes 
will be estimated using a locally produced and validated 
 on N
ovem
ber 20, 2020 by guest. P
rotected by copyright.
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2020-039231 on 18 N
ovem
ber 2020. D
ow
nloaded from
 
7Lowe NM, et al. BMJ Open 2020;10:e039231. doi:10.1136/bmjopen-2020-039231
Open access
food atlas. A total of five recall interviews, three in phase 1 
and two in phase 2, will provide a good estimate of typical 
nutrient intake in both the rainy and the dry seasons. 
The dietary intake data will be analysed using WinDiets 
Research Software (2015), Robert Gordon University UK, 
augmented with data from recent Indian food composi-
tion database,21 and laboratory analysis of study- specific 
wheat flour and commonly consumed recipes made by 
the Pakistan based study nutritionist.
The bioavailability of zinc and iron will be measured 
from foods made from wheat flour (both fortified and 
control), including paratha, chapatti and roti breads. 
Human intestinal Caco-2 cell line, when used together 
with in vitro digestion, permits the analysis of complex 
interactions in whole foods, for example, the digestibility 
of plant cell walls and the release of iron in a form that 
is available for absorption.22 This model will be used to 
assess zinc and iron availability from control and biofor-
tified (Zincol-2016) wheat lines and food products made 
from these flours (at King’s College London, UK). Mathe-
matical modelling methods combining phytate, iron, and 
zinc intake will be used to predict absorption levels from 
the local diet.23
Withdrawal and lost to follow-up
Households and individuals are free to withdraw from the 
trial at any time. If a household or individual withdraws 
from the study, their data will remain on file and be used 
in the final analyses, as indicated on the study consent 
form.
Households or individuals that move away from the 
study catchment area will leave the trial and no attempt 
will be made to follow them up. Any data collected from 
the household will remain on file and be used in the final 
analyses.
Throughout the intervention period (November 2019 
to November 2020), community engagement events and 
information sessions will be regularly conducted to deal 
with any community concerns as they arise and encourage 
ongoing participation in the study. Any serious commu-
nity concerns that arise during the intervention period 
will be addressed and resolved with through the commu-
nity Jirga system.
Data collection and storage
Sample analysis will take place in specialist laboratories 
in the UK and Pakistan. Quality control data (refer-
ence materials, detection limits) and full protocols will 
be reported with the data to ensure that all information 
is stored together. Several data types will be generated 
in this project, which will be managed compliant with 
standard United Kingdom Research and Innovation 
(UKRI) policies (https:// bbsrc. ukri. org/ documents/ 
data- sharing- policy- pdf/). The University of Central 
Lancashire (UCLan) will be the Data Hub for the project. 
Data protection and management systems will be clearly 
communicated to all project partners. UCLan adheres 
to an Open Data policy and has an open data repository 
(UCLan Data). Metadata will be collected in the form of 
‘read me’ files according to the Dublin Core Metadata 
Initiative. The study will generate personal data from the 
analysis of biological samples. Participants will be given a 
unique ID number on recruitment, and this will be used in 
all data files. The list of names associated with the unique 
ID numbers will only be known by the project manager 
and will be stored in a locked filing cabinet. Biolog-
ical samples will be labelled using the same unique ID 
numbers. Samples will be shipped to international labo-
ratories for analysis using a secure courier service. Data 
entry templates (in Excel) will be codeveloped by UCLan 
and Abaseen Foundation, with variables clearly defined 
in ‘read me’ files. Data will be transferred to UCLan in 
password- protected files using OneDrive. UCLan systems 
are automatically backed up. Data entry will be checked 
and cleaned prior to analysis, which will be conducted at 
UCLan. Data and metadata will be securely stored in a 
project database and reported on publication.
Statistical analysis plan
The reporting and presentation of this trial will similarly 
be in accordance with the CONSORT guidelines for 
cluster randomised trials,13 with the primary comparative 
analysis being conducted on an intention- to- treat basis. 
The statistical analysis protocol will be undertaken on 
both primary and secondary continuous data using an 
intention to treat basis, whereby participants will be anal-
ysed by the arm to which their cluster was randomised. To 
account for the cluster- based nature of the randomisation 
process, linear random- effects modelling for the primary 
and secondary outcomes will be used to compare the two 
groups. We expect to adjust the models to account for 
covariate values at baseline. A significance level of 5% 
will be adopted, and effectiveness estimation will include 
both point and 95% CI estimates.
Ethics and dissemination
Ethical approval for the research has been granted from 
the lead University (UCLan) (unique reference number: 
STEMH 1014), the National Bioethics Committee of 
Pakistan (NBC-433) and the collaborating institution 
in Pakistan, KMU (DIR/KMU- EB/BZ/000683). All 
data collected will be anonymised and stored on secure 
servers, with data protection protocols followed when 
information is shared between participating institutions. 
The final study methods (including any modifications) 
will be published in peer- reviewed journals, alongside the 
study outcomes on completion of the data analysis.
Authorship will be restricted to those who have contrib-
uted to the design of the study, data collection and anal-
ysis, in accordance with the International Committee of 
Medical Journal Editors guidance.24 The protocol used to 
decide the order of authorship will be published in the 
paper acknowledgements. In addition to peer- reviewed 
journals, findings will be disseminated to the scientific 
community via conference presentations and abstracts. 
The findings of the study will be communicated to the 
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study participants through the village elders at an appro-
priate community forum. More widely, the AFPK can 
access some of the most difficult- to- reach communities in 
KP and the Federally Administered Tribal Area, including 
through tribal networks, local Jirga and religious leaders. 
We will work with our contacts in the agriculture sector 
to exchange knowledge with key actors. For example, the 
Agricultural Services Department of FFC provides soil, 
water, fertiliser and plant analysis and recommendation 
services (in addition to other farmer education/training 
programmes) to the farming community throughout 
the country. Project partners and collaborators are well 
connected to ensure that new evidence can support 
policy.
A strategic advisory group (SAG), comprised of key 
international stakeholders, policy- makers and commu-
nity members, will provide external guidance and help 
ensure that the project remains relevant to the end- users. 
The SAG will be consulted by email throughout the 2- year 
project, particularly during the first 6- month consultation 
period and will meet by video conference every 6 months.
CONCLUSION
The RCT described in this protocol paper is part of a 
larger programme of research that aims to generate data 
on the effectiveness, acceptability and feasibility of a wheat 
biofortification strategy for the improvement of micronu-
trient status in the Pakistan context. Our approach aligns 
with the Government of Pakistan’s Strategy for Improving 
Nutrition, fundamental to which is the generation of new 
evidence to inform policy at national and international 
levels.
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